Compare CIG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIG | IBRX |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.1B |
| IPO Year | N/A | 2015 |
| Metric | CIG | IBRX |
|---|---|---|
| Price | $2.19 | $9.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.60 |
| AVG Volume (30 Days) | 5.1M | ★ 31.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $0.38 | $93.25 |
| Revenue Next Year | N/A | $149.39 |
| P/E Ratio | $9.38 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $1.59 | $1.83 |
| 52 Week High | $2.41 | $12.43 |
| Indicator | CIG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 64.84 |
| Support Level | $1.92 | $2.23 |
| Resistance Level | $2.28 | N/A |
| Average True Range (ATR) | 0.06 | 1.31 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 22.41 | 62.08 |
Cia Energetica DE Minas Gerais - Cemig, formerly Energy Company of Minas Gerais, is a Brazilian power company that generates, transmits, and distributes electricity. As one of the power companies in Brazil, the firm operates across Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power through hydroelectric resources and, secondarily, through thermal and wind resources.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.